<DOC>
	<DOCNO>NCT02389894</DOCNO>
	<brief_summary>To evaluate efficacy safety embolic protection device reduce ischemic brain injury patient undergoing surgical aortic valve replacement ( AVR ) .</brief_summary>
	<brief_title>Neuroprotection Patients Undergoing Aortic Valve Replacement</brief_title>
	<detailed_description>This multicenter randomize trial patient diagnose calcific aortic stenosis ( AS ) plan AVR randomize 1 ) treatment arm Edwards Life Science filter cannula filter stand alone cannula 2 ) treatment arm CardioGard cannula versus 3 ) standard care 1:1:1 ratio .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Brain Infarction</mesh_term>
	<criteria>Age ≥ 60 year Planned scheduled surgical aortic valve replacement via full minimalaccess sternotomy ( use central aortic perfusion cannulae ) calcific aortic stenosis legally market valve No evidence neurological impairment define NIHSS ≤1 modify Rankin scale ( mRS ) ≤ 2 within 7 day prior randomization Ability provide inform consent comply protocol Contraindication legally market embolic protection device ( e.g . aneurysm ascend aorta , aortic trauma , porcelain aorta , know sensitivity heparin ) History clinical stroke within 3 month prior randomization Cardiac catheterization within 3 day plan aortic valve replacement Cerebral aortic arch arteriography intervention within 3 day plan aortic valve replacement Active endocarditis time randomization Anticipated inability tolerate contraindication MRI ( e.g. , know intolerance MRI , permanent pacemaker baseline expect implantation permanent pacemaker ) Any concomitant aortic procedure root replacement Concomitant surgical procedure CABG , mitral annuloplasty , leave atrial appendage ( LAA ) excision exclusion , atrial septal defect ( ASD ) closure patent foramen ovale ( PFO ) closure Clinical sign cardiogenic shock treatment IV inotropic therapy prior randomization Concurrent participation interventional ( drug device ) trial</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Embolic Protection Device</keyword>
	<keyword>Stroke</keyword>
	<keyword>Brain Infarction</keyword>
	<keyword>atheroma</keyword>
	<keyword>Aortic Valve Replacement</keyword>
</DOC>